Although the purpose of this study was to use machine learning methods to develop an immunotherapy resistance score to predict anti-PD1/PD-L1 response in all types of cancers, the results of the study are particularly relevant to melanoma as one of the two external validation cohorts used was a melanoma immunotherapy cohort. The gene discussed is PDCD1; the disease is cancer.